Welcome to our dedicated page for Clorox Co Del SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clorox Company (NYSE: CLX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a consumer products manufacturer in the polish and other sanitation good manufacturing industry. This SEC filings page aggregates those disclosures and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
Key filings for CLX include annual reports on Form 10-K, which typically describe the company’s business segments—Health and Wellness, Household, Lifestyle and International—along with risk factors, discussion of strategy and detailed financial statements. Quarterly reports on Form 10-Q update investors on interim performance, including segment results, margin drivers, cash flow and the impact of initiatives such as the U.S. enterprise resource planning (ERP) transition and portfolio changes like the divestiture of the Better Health Vitamins, Minerals and Supplements business.
Clorox also uses current reports on Form 8-K to disclose material events. Recent 8-K filings have covered quarterly and annual financial results, supplemental financial information, and matters submitted to a shareholder vote at the annual meeting, including director elections, advisory votes on executive compensation and ratification of the independent registered public accounting firm. Other 8-Ks may address leadership changes or other significant corporate developments.
The company’s proxy statement on Form DEF 14A provides additional detail on governance, board composition, executive compensation, strategic priorities such as the IGNITE strategy and oversight of areas like risk management and sustainability. For those interested in ownership and compensation, this document is a primary source.
On this page, filings are updated as they are released to EDGAR. AI-generated highlights and plain-language explanations help clarify complex topics such as non-GAAP measures (for example, organic sales growth, adjusted EBIT and adjusted EPS), the effects of the ERP transition on reported results, and the rationale behind portfolio actions. Users can also review any available insider-related disclosures, such as Form 4 filings, to see reported transactions by directors and officers.
Whether you are analyzing Clorox’s segment performance, reviewing governance practices, or tracking shareholder votes and executive compensation, this filings hub offers structured access to the company’s regulatory record with tools designed to make lengthy documents more approachable.
Luc Bellet, EVP and Chief Financial Officer of The Clorox Company (CLX), reported an open-market purchase of 7,368 shares of Clorox common stock on 09/16/2025 at a reported price of $124.85 per share. After the purchase, the filing shows Mr. Bellet beneficially owned 19,546 shares. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
The filing also discloses restricted stock units that will vest in four equal installments on October 5, 2026, October 5, 2027, October 5, 2028, and October 5, 2029. No derivative transactions, dispositions, or additional cash- or price-related terms beyond the reported purchase price are included in the document.
Luc Bellet, EVP and Chief Financial Officer of The Clorox Company (CLX), reported an open-market purchase of 7,368 shares of Clorox common stock on 09/16/2025 at a reported price of $124.85 per share. After the purchase, the filing shows Mr. Bellet beneficially owned 19,546 shares. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
The filing also discloses restricted stock units that will vest in four equal installments on October 5, 2026, October 5, 2027, October 5, 2028, and October 5, 2029. No derivative transactions, dispositions, or additional cash- or price-related terms beyond the reported purchase price are included in the document.
Linda J. Rendle, Chief Executive Officer and Director of The Clorox Company (CLX), reported an award of 34,281 shares of Common Stock on 09/16/2025 at a reported price of $124.85 per share, increasing her beneficial ownership to 167,537 shares. The filing indicates these shares are Restricted Stock Units that will vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028, and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
Linda J. Rendle, Chief Executive Officer and Director of The Clorox Company (CLX), reported an award of 34,281 shares of Common Stock on 09/16/2025 at a reported price of $124.85 per share, increasing her beneficial ownership to 167,537 shares. The filing indicates these shares are Restricted Stock Units that will vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028, and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
Eric H. Reynolds, Executive Vice President and Chief Operating Officer of The Clorox Company (CLX), reported transactions dated 09/04/2025. The filing shows an exercise of stock options (derivative) to acquire 15,210 shares at an exercise/conversion price of $111.60, and a related non-derivative acquisition of 15,210 shares (reported at $111.60). The report also discloses a sale of 15,041 shares at a weighted average price of $123.7848 (trade prices ranged $123.731–$123.84). Following these transactions the reporting person is shown as beneficially owning 69,262 shares after the acquisition and 54,221 shares after the sale. The form is signed by an attorney-in-fact on 09/08/2025.
Clorox Company (CLX) Form 144 notice reports a proposed sale of 15,041 shares of Common stock through UBS Financial Services on the NYSE with an aggregate market value of $1,861,847.74. The filing shows the shares were acquired and are proposed to be sold on 09/04/2025 following an employee stock option exercise paid in cash. The filer states there have been no securities sold by the account in the past three months and affirms no undisclosed material adverse information is known. The form is a routine Rule 144 notice documenting the intended compliant sale.
The Clorox Company reported fiscal 2025 net sales of $7.1 billion and employed about 7,600 people worldwide. Net sales were essentially flat for the year while the company grew overall market share and expanded gross margin. Diluted net earnings per share rose 190%, driven largely by the absence of prior-period Argentina divestiture losses and a prior pension settlement charge, together with higher current‑period volume, cost savings and cyberattack insurance recoveries, partially offset by the loss on the divestiture of the Better Health VMS business, unfavorable mix and higher trade promotion spending.
Clorox completed the Better Health VMS divestiture in September 2024, is winding down the Glad venture with P&G (P&G’s 20% to be acquired by Clorox at fair market value upon termination), and continues a multi‑year transformational program including ERP and digital investments with total incremental spend expected to be $570–$580 million. The company paid $602 million in dividends in FY2025 and announced a 2% dividend increase in July 2025. Key concentrations and metrics disclosed include >80% of sales from brands ranking No.1 or No.2 in category, product-line mix (Cleaning 44%, Bags & Wraps 15%, Food 12%, Cat Litter 10%), and Walmart accounting for 27% of consolidated net sales.